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A B S T R A C T
This systematic review with meta-analysis sought to determine the efﬁcacy, safety of implantation of
cardiac resynchronization therapy (CRT) in mild heart failure (HF). Medline, Embase, Elsevier, and
Sciences online database as well as Google scholar literature were used for selecting appropriate studies
with randomized controlled design. The literature search of all major databases retrieved 2035 studies.
After screening, a total of 10 trials were identiﬁed that reported outcomes of interest. Pooled analysis was
performed on left ventricular (LV) ejection fraction (P < 0.001), LV end-diastolic volume (P < 0.001), LV
end-systolic volume (P < 0.001), LV end-diastolic diameter (P < 0.001), LV end-systolic diameter
(P < 0.001), incidence of progression of heart failure (P < 0.001), mortality (P = 0.06), infection (P = 0.1),
and pneumothorax (P = 0.08). Overall, implantation of CRT in patients with asymptomatic and mild HF
resulted in improved cardiac function, decreased progression of HF, trend to decrease of mortality in
short to long-term follow-up.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Heart failure (HF) is considered as an epidemic disease of the
modern era nowadays.1–3 Despite recent developments in HF
management, the morbidity and mortality in this clinical
syndrome remain unacceptably high and patients suffer from
debilitating symptoms adversely affecting their quality of life.1–3
Failure may be compounded in patients with intra-ventricular
conduction delay possibly due to a loss of ventricular synchroni-
zation.4 Regarding that importance of adverse events in this
clinical syndrome, there is an emerging emphasis on understand-
ing the progression from heart failure risk factors to asymptomatic
ventricular dysfunction and eventually to symptomatic heart
failure and death.1–4 The placement of an implantable cardiover-
ter-deﬁbrillator (ICD) improves survival and reduces the risk of
sudden death. However, life-prolonging deﬁbrillator therapy is* Corresponding author at: Cardiovascular Center, Shahid Sadoughi University of
Medical Sciences, Arsalan Street, Hassan-beigi Blvd, Yazd 8916936637, Iran.
E-mail address: S.alihassan.cardiosurg@gmail.com (S. Ali-Hassan-Sayegh).
1 These authors contributed equally to this review.
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earlier reverse therapy, Indian Heart J. (2016), http://dx.doi.org/10.1
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0019-4832/ 2016 Published by Elsevier B.V. on behalf of Cardiological Society of
creativecommons.org/licenses/by-nc-nd/4.0/).associated with an increased risk of ﬁrst and recurrent HF events.5
Cardiac resynchronization therapy (CRT) can improve symptoms
of HF, quality of life, exercise capacity, and left ventricle function
when used in patients suffered from symptomatic HF with New
York Heart Association (NYHA) functional class III or ambulatory
class IV with a wide QRS complex.6,7 Recently, the ACCF/AHA
guidelines limited the Class I indication for CRT to patients with a
QRS duration 150 ms.8,9 However, a QRS duration of 120–150 ms
is still recommended as the Class I indication in the European
Society of Cardiology (ESC) guidelines if the patient has an LBBB
pattern and depressed LVEF.9 Also, according to Tracey et al., CRT
can be useful (Class IIa indication) for patients who have LVEF less
than or equal to 35%, sinus rhythm, a non-LBBB pattern with a QRS
duration greater than or equal to 150 ms, and NYHA class III/
ambulatory class IV symptoms on GDMT.8 Regarding that
progression of clinical symptoms from mild to severe HF partially
resulting from insufﬁcient and inappropriate treatments, current
investigations focus on introducing treatments with ability of
earlier reverse of HF symptoms. Several studies have reported the
efﬁcacy and safety of implantation of CRT in asymptomatic or mild
HF. However, data from RCTs are limited and so far largely
inconclusive. This systematic review with meta-analysis sought toesynchronization therapy in patients with mild heart failure is an
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changes in left ventricular ejection fraction (LVEF), left ventricular
end diastolic (LVEDV) and end systolic volumes (LVESV), left
ventricular end diastolic (LVEDD) and end systolic diameters
(LVESD), left ventricular end systolic volume index (LVESVI), and
impact on incidence of HF, mortality, infection, pneumothorax, and
hematoma required intervention.
2. Methods and materials
2.1. Literature search
A comprehensive literature search was conducted in major
electronic databases (Medline/Pubmed, Embase, Elsevier, Web of
Knowledge, Sciences online database and Google Scholar) from
their inception through July 25, 2014 to identify the RCTs reporting
the effects of CRT on echocardiographic results and clinical
outcomes in patients with mild HF. Predeﬁned search terms
included: ‘‘cardiac resynchronization therapy’’, ‘‘CRT’’, ‘‘biventri-
cular pacing’’, ‘‘biventricular pacemaker’’, and ‘‘heart failure’’, ‘‘HF’’,
‘‘mild HF’’. No language restrictions were applied. All retrieved
references of the included RCTs were also reviewed to determine
additional studies not indexed in the common databases. Studies
were included into the analysis when they met the following
criteria: (1) RCT, (2) comparison of CRT with a control group, and
(3) reporting data on the echocardiographic results and clinical
outcomes according to our review-checklist. In addition, abstracts
without peer-review publications of manuscripts were not
included.
2.2. Data extraction and outcome measures
Two investigators (S.A.-H.-S. and A.A.K.-B.) extracted the data
independently, and discrepancies were resolved via a consensus
standardized abstraction checklist used for recording data in each
study. Data retrieved from the trials included: author’s name,
mean age, gender, sample size, study design, type of controls,
duration of follow-up, primary and secondary endpoints, NYHA
class, consumption of beta blocker, diuretics, angiotensin con-
verting enzyme inhibitors and angiotensin receptor blockers, Jadad
score. For each group the following data were recorded: LVEF,
LVESV, LVEDV, LVEDD, LVESD, LVESVI, incidence of heart failure,
mortality, infection, pneumothorax, and hematoma required
intervention. For exploration of heterogeneity among trials, a
subgroup analysis of disparities in the patients’ characteristics was
performed for (1) average age (<65 years vs. 65 years), (2)
percentage of male gender (<80% vs. 80%), (3) follow-up duration
(6 months vs. >6 months), (4) sample size (500 vs. >500).
2.3. Statistical analysis, publication bias and quality assessment
Data were analyzed by STATA version 11.0 utilizing METAN and
METABIAS modules. The effect sizes measured were odds ratio
(OR) with 95% conﬁdence interval (CI) for categorical variables.
Regarding non-categorical data, weighted mean difference (WMD)
with 95% CI was used for calculating differences between
intervention and control groups. OR <1 favored CRT and OR >1
favored control. RCTs with no events in the 2 arms were discarded
from pooled analysis. Forest plots were created for each outcome. A
value of P < 0.1 for Q test or I2 > 50% indicated signiﬁcant
heterogeneity among the studies. Heterogeneity among trials
was accounted for by applying a random effect model when
indicated. The presence of publication bias was evaluated using the
Begg and Egger tests. Quality assessment of RCTs was performed
using the Jadad score. The Jadad score assesses 3 items including
randomization (0–2 points), blinding of study (0–2 points) andPlease cite this article in press as: Ali-Hassan-Sayegh S, et al. Cardiac r
earlier reverse therapy, Indian Heart J. (2016), http://dx.doi.org/10.1withdrawals and dropouts (0–1 points). Higher scores indicate
better reporting (‘‘high’’ quality: 5; ‘‘good’’ quality: 3–4; ‘‘poor’’
quality: 0–2). Results were considered statistically signiﬁcant at a
P-value < 0.05.
3. Results
3.1. Literature search strategy and included trials
Literature search retrieved 2035 studies from screened
databases of which 1769 (86.9%) were excluded after initial
review. Of 266 primarily included studies, 256 were excluded after
detailed evaluation due to insufﬁcient reporting of endpoints of
interest. The ﬁnal analysis included 10 RCTs.
3.2. Study characteristics, effect measures and clinical outcomes
3.2.1. Left ventricular ejection fraction
A total of 2582 patients were included from 5 RCTs reporting
data on LVEF. Patient population of RCTs ranged from 36 to
1820 patients (Table 1). From all patients, 1463 were allocated to
CRT and 1119 to the control group. Mean increase in LVEF for all
trials were 5.1  5.6 with 6.78  6.14 for CRT and 3.42  5.24 for the
control group (Table 2). Applying a random effect model, pooled
analysis revealed that CRT succeeded in increasing ejection fraction
mildly with a WMD of 2.88 (95% CI: 2.77–3; P < 0.001) (Fig. 1). There
was a signiﬁcant heterogeneity among the studies (chi-
squared = 857.25, I2 = 99.5%, P < 0.001). The subgroup analysis is
presented in Table 3.
3.2.2. Left ventricular end diastolic and end systolic volume
A total of 2042 cases were included from 3 RCTs reporting data
on LVEDV and LVESV. Patient population of RCTs ranged from 36 to
1820. From all patients, 1193 were allocated to CRT and 849 to the
control group (Table 1). Mean decrease in LVEDV for all trials was
29.31  52.2 with 44.6  59.9 for CRT and 14.5  44.5 for the
control group, and mean decrease in LVESV for all RCTs was
32.1  49.6 with 46.7  56.4 for CRT and 15.7  42.8 for the
control group, respectively (Table 2). Applying a random effect model,
pooled analysis reported that CRT therapy could signiﬁcantly
decrease LVEDV (WMD of 37.31; 95% CI: 39.53 to 35.1;
P < 0.001) and LVESV (WMD of 39.02; 95% CI: 41.2 to 36.84;
P < 0.001). There was no signiﬁcant heterogeneity among the studies
for LVEF and LVESV analyses (I2 = 0.0% for both).
3.2.3. Left ventricular end diastolic diameter and end systolic
diameter
A total of 2346 cases were included from 3 RCTs reporting data
on LVEDD and LVESD. Patient population of RCTs ranged from 36 to
1820. From all patients, 1353 were allocated to CRT and 993 to the
control group (Table 1). Mean decrease in LVEDD for all trials was
2.4  3.4 with 4.1  3.7 for CRT and 0.8  3.1 for the control
group, and mean decrease in LVESD for all RCTs was 3.6  4 with
5.7  4.4 for CRT and 1.6  3.6 for the control group, respectively
(Table 2). Applying a random effect model, pooled analysis reported
that CRT could signiﬁcantly decrease LVEDD (WMD of 2.98; 95% CI:
3.1 to 2.85; P < 0.001) and LVESD (WMD of 3.35; 95% CI: 3.48
to 3.22; P < 0.001). There was a signiﬁcant heterogeneity among the
studies for LVEDD and LVESD (I2 = 99.1% for LVEDD and I2 = 99.6% for
LVESD).
3.2.4. Left ventricular end systolic volume index
A total of 2082 patients were included from 2 RCTs reporting
data on LVEF; 1269 were allocated to CRT and 813 to the control
group. Applying a random effect model, pooled analysis revealed
that CRT succeeded in signiﬁcantly decreasing LVESV index with aesynchronization therapy in patients with mild heart failure is an
016/j.ihj.2016.08.001
Table 1
Demographic data of included studies.
Author (references) N Mean age (yrs) Male (%) Mean LVEF (%) Mean LVEDV
(ml)
Mean LVESV
(ml)
ORS (ms)
CRT C CRT C CRT C CRT C CRT C CRT C CRT C
MADIT CRT10 1089 791 65 64 74.7 75.6 24 24 245 251 175 179 699 476
Greater-earth trial11 61 60 61 61 75 75 24 24 211 211 161 161 155 155
Gierula12 25 25 77 77 64 64 39 41 N.D. N.D. N.D. N.D. 168 159
REVERSE trial13 180 82 61.7 60.4 79 85 28.1 27.8 256 257 186 186 155 157
CONTAKT trial14 245 245 66 66 85 83 21 22 N.D. N.D. N.D. N.D. 160 156
Van Geldorp15 19 17 64 67 78.9 76.4 36 36 163 147 109 98 193 196
RAFT trial16 894 904 66.1 66.2 84.8 81 22.6 22.6 N.D. N.D. N.D. N.D. 157 158
Narrow-CRT trail17 60 60 65 68 88 83 28 29 201 194 148 136 107 104
MIRACLE trial18 85 101 63 63.1 88.2 90.1 24.4 24.6 337 329 260 252 166 165
CARE-HF trial19 86 89 64 64 77 77 24.8 24.8 122 122 N.D. N.D. 160 160
Author (references) Beta-blocker Diuretic Design Follow-up Jadad
CRT C CRT C
MADIT CRT10 93.3 93.2 75.7 72.9 ICD + CRT vs. ICD 2.4 years 4
Greater-earth trial11 94 94 N.D. N.D. ICD + CRT vs. ICD + LV 6 months 4
Gierula12 56 52 N.D. N.D. CRT vs. RV 6 months 4
REVERSE trial13 95 90 84 87 ICD + CRT (on) vs. ICD + CRT (off) 24 months 4
CONTAKT trial14 48 46 88 83 ICD + CRT (on) vs. ICD + CRT (off) 6 months 4
Van Geldorp15 N.D. N.D. N.D. N.D. ICD + CRT vs. ICD + RV 6 months 3
RAFT trial16 90.4 89 84.7 83.6 ICD + CRT vs. ICD + RV 40 months 4
Narrow-CRT trail17 87 92 85 87 CRT deﬁbrillator vs. ICD 12 months 4
MIRACLE trial18 63.5 63.5 87.1 80.2 ICD + CRT (on) vs. ICD + CRT (off) 6 months 4
CARE-HF trial19 81 81 54 54 CRT vs. no CRT 50 months 4
Table 2
Clinical outcomes of included studies.
Author LVEF (%) LVEDV LVESV LVEDD LVESD
CRT C CRT C CRT C CRT C CRT C
MADIT CRT10 11  5 3  3 52.2  33.2 14.7  14.4 57.3  31.2 18.1  16.3 6  3.4 1.5  1.5 8.9  4.4 2.5  2.2
Greater-earth11 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.
Gierula12 9  6 1.5  5.3 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.
REVERSE trial13 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.
CONTAKT trial14 5.1  0.7 2.8  0.7 N.D. N.D. N.D. N.D. 2.4  0.8 0  0.8 3.2  0.8 0.5  0.8
Van Geldorp15 5  11 12  11 39  70.5 13  57.3 41  61 15  55.3 4  7 1  7 5  8 2  8
RAFT trial16 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.
Narrow-CRT trail17 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.
MIRACLE trial18 3.8  8 0.8  6.2 41  76 16  62 42  77 14  57 N.D. N.D. N.D. N.D.
CARE-HF trial19 N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.
Author (references) LVESV index HF Mortality Infection Pneumothorax Hematoma
required
intervention
CRT C CRT C CRT C CRT C CRT C CRT C
MADIT CRT10 28.7  15.5 9.1  8.2 136 140 36 18 12 5 19 6 36 18
Greater-earth11 N.D. N.D. 8 4 2 2 N.D. N.D. N.D. N.D. N.D. N.D.
Gierula12 N.D. N.D. 0 2 1 2 N.D. N.D. N.D. N.D. N.D. N.D.
REVERSE trial13 27.5  31.8 2.7  25.8 13 14 10 7 N.D. N.D. N.D. N.D. N.D. N.D.
CONTAKT trial14 N.D. N.D. 32 39 11 16 N.D. N.D. N.D. N.D. N.D. N.D.
Van Geldorp15 N.D. N.D. N.D. N.D. 0 0 N.D. N.D. N.D. N.D. N.D. N.D.
RAFT trial16 N.D. N.D. 174 236 130 162 21 16 11 8 14 11
Narrow-CRT trail17 N.D. N.D. 5 11 4 5 2 1 N.D. N.D. 1 1
MIRACLE trial18 N.D. N.D. 7 19 2 2 N.D. N.D. N.D. N.D. N.D. N.D.
CARE-HF trial19 N.D. N.D. N.D. N.D. 23 27 N.D. N.D. N.D. N.D. N.D. N.D.
Long-term follow-up
Author Follow-up Design Conclusion
MADIT trial20 7 years ICD + CRT vs. ICD This study indicated that in patients with mild heart-failure symptoms, left ventricular dysfunction,
and left bundle-branch block, early intervention with CRT-D was associated with a signiﬁcant long-
term survival beneﬁt
REVERSE trial21 5 years ICD + CRT (on) vs.
ICD + CRT (off)
This study indicated that in patients with mild HF, CRT produced reverse LV remodeling
accompanied by very low mortality and need for heart failure hospitalization. These effects were
sustained over 5 years. Cardiac resynchronization therapy in addition to optimal medical therapy
produces long-standing clinical beneﬁts in mild heart failure.
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Fig. 1. Forest plot of weighted mean differences (WMD) for treatment with cardiac resynchronization therapy on left ventricle ejection fraction.
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no signiﬁcant heterogeneity among the studies (chi-
squared = 1.92, I2 = 48%, P = 0.1).
3.2.5. Incidence of progression of heart failure
A total of 4847 patients were included from 8 RCTs reporting
data on the incidence of progression of HF. Patient population of
RCTs ranged from 50 to 1820 subjects (Table 1). From all cases,Table 3
Subgroup analysis for clinical outcomes.
Subgroup Studies (N) Odd ratio or SMD (95% CI) P-value
S.G.A for left ventricle ejection fraction (LVEF) according to SMD
Age (years)
65 2 1.67 (1.57 to 1.77) <0.001
>65 3 2.62 (2.38 to 2.86) <0.001
Male (%)
80 4 1.99 (1.89 to 2.09) <0.001
>80 1 0.42 (0.13 to 0.71) 0.004
Follow up
6 months 4 1.75 (1.57 to 1.93) <0.001
>6 months 1 1.85 (1.74 to 1.96) <0.001
Sample size
500 4 1.75 (1.57 to 1.93) <0.001
>500 1 1.85 (1.74 to 1.96) <0.001
S.G.A for left ventricle end diastolic and systolic diameter (LVEDD and
LVESD) according to SMD
Age (years)
65 1 1.60 (1.71 to 1.50) <0.001
>65 2 0.26 (2.90 to 2.41) <0.001
Male (%) All studies have male percentage less than
80%
80
>80
Follow up
6 months 2 2.66 (2.90 to 2.41) <0.001
>6 months 1 1.60 (1.71 to 1.50) <0.001
Sample size
500 2 2.66 (2.90 to 2.41) <0.001
>500 1 1.60 (1.71 to 1.50) <0.001
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(Tables 1–2). The overall incidence of heart failure was 17.33%
ranging from 4% to 22.8%. Progression of heart failure occurred in
14.2% in CRT group and 21.05% in control group (Table 2). Pooled
treatment effect analysis revealed that CRT could signiﬁcantly
decrease the incidence of progression of heart failure with an OR of
0.64 (95% CI: 0.55–0.74; P < 0.001) using a ﬁxed model (Fig. 2). No
signiﬁcant heterogeneity was observed among the RCTs (Chi-
squared = 8.76, I2 = 20.1%, P = 0.2). Begg and Egger tests showed no
potential publication bias among the included RCTs (Begg test,
P = 1.0; Egger test, P = 1.0).
3.2.6. Mortality
Ten RCTs (5058 patients) reported data on death. Mortality
occurred in 7.98% in CRT group and 10.41% in control group
(Table 2). In fact 1 out of 10 comparisons did not present any
postoperative death events in 2 comparative arms, therefore, theFig. 2. Forest plot of odds ratio (OR) for treatment with cardiac resynchronization
therapy on progression of heart failure.
esynchronization therapy in patients with mild heart failure is an
016/j.ihj.2016.08.001
Fig. 3. Forest plot of odds ratio (OR) for treatment with cardiac resynchronization
therapy on incidence of mortality.
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analysis. Pooled treatment effect analysis revealed that CRT had a
statistical trend toward reduction in mortality with an OR of 0.83
(95% CI: 0.68–1.01; P = 0.06) using a ﬁxed model (Fig. 3). No
signiﬁcant heterogeneity was observed among the RCTs (chi-
squared = 3.95, I2 = 0.0%, P = 0.8). Begg and Egger tests showed no
potential publication bias among the included RCTs (Begg test,
P = 0.655; Egger test, P = 0.655).
3.2.7. Infection
Three RCTs (3738 cases) reported data on the occurrence of
infection. Overall incidence of infection was 1.54%: 1.71% in CRT
group and 1.29% in control group (Tables 1–2). Pooled analysis
indicated that CRT group was associated with a trend toward
increased incidence of infections with an OR of 1.44 (95% CI: 0.83–
2.47; P = 0.1) using a ﬁxed model (Fig. 4). No signiﬁcant
heterogeneity was observed among the RCTs (chi-squared = 0.18,
I2 = 0.0%, P = 0.9). Begg and Egger tests found no potential
publication bias among the included RCTs (Begg test, P = 0.117;
Egger test, P = 0.117).
3.2.8. Pneumothorax
Two RCTs (3618 cases) reported data on the occurrence of
pneumothorax. Overall incidence of pneumothorax was 1.21%;Fig. 4. Forest plot of odds ratio (OR) for treatment with cardiac resynchronization
therapy on incidence of infection.
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revealed that CRT group had trend toward increased incidence of
pneumothorax with an OR of 1.75 (95% CI: 0.91–3.33; P = 0.08)
using a ﬁxed model. No signiﬁcant heterogeneity was observed
among the RCTs (chi-squared = 0.42, I2 = 0.0%, P = 0.5).
3.2.9. Hematoma required intervention
A total of 3738 patients were included from 3 RCTs reporting
data on the incidence of hematoma. From these cases, 2043 were
allocated to CRT and 1695 to the control group. The overall
incidence of hematoma was 2.16% ranging from 1.3% to 2.9%.
Hematoma occurred in 2.49% in CRT group and 1.76% in control
group. Pooled analysis indicated that CRT did not signiﬁcantly
increase the incidence of hematoma with an OR of 1.32 (95% CI:
0.83–2.09; P = 0.2) using a ﬁxed model. No signiﬁcant heterogene-
ity was observed among the RCTs (chi-squared = 0.05, I2 = 0.0%,
P = 0.9).
4. Discussion
Early diagnosis and appropriate treatment are of critical
importance in HF: if the disease is controlled at earlier stages,
survival and quality of life in patients are more likely to improve.1–
3 According to guidelines, CRT when used in patients with
moderate and severe HF, will be able to signiﬁcantly improve
clinical symptoms, quality of life, return to work, physical
activities, and left ventricular function.2–4 Therefore, beneﬁcial
effects of CRT implantation in patients with NYHA class III and IV
resulted in effective and efﬁcient treatment before the patient
requires heart transplant.2–4 It is obvious that in HF, decreased left
ventricular function results in increasing remaining blood volume
at the end of systole and diastole with consequently increasing left
ventricular diameters and decreasing LVEF. Therefore, the more
this vicious cycle continues, the higher the failure grade and the
more the clinical symptoms appear.
The main ﬁndings of our study indicated that CRT could
signiﬁcantly reduce remaining blood volume and diameters of the
left ventricle at the end of systole and diastole, and also increase
LVEF. Given the fact that the follow-up period might be an
important factor to detect an improvement in patients with mild
HF, another noted difference is that we used extended follow-up of
the REVERSE Trial: 24 months clinical and left ventricle remodeling
which were reported by the European cohort.13 REVERSE Trial
suggested that clinical outcomes and LV function were improved
and LV dimensions were decreased in a patient population in
NYHA class I or II.13
Our ﬁndings revealed that CRT could considerably prevent
progression of HF, therefore, in patients with mild HF, CRT
implantation at earlier stages of HF could be used in order to
prevent worsening of clinical signs and decrease the cases of severe
HF requiring heart transplant, thus being considered as an earlier
reverse therapy. Lubitz et al. reported that CRT in patients with
mild HF symptoms, left ventricular dysfunction, sinus rhythm and
prolonged QRS duration could decrease HF events.26 In the current
study, CRT was also shown to have a strong tendency toward
decreasing mortality. A study by Tu et al. also stated that CRT could
signiﬁcantly decrease all-cause mortality which conﬁrms our
deduction.27 MADIT-CRT showed that CRT combined with ICD
decreased the risk of heart failure events in relatively asymptom-
atic patients with LVEF less than 30% and wide QRS complex. The
absence of an observed mortality beneﬁt in this trial was probably
due to a very low annual mortality rate (3%) throughout the course
of the study period.10
A foreign material in the body may develop complications
including hemorrhage related to implant placement, such as
hematoma required intervention and infection.25–27 The results ofesynchronization therapy in patients with mild heart failure is an
016/j.ihj.2016.08.001
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to develop infection and pneumothorax, however the incidence of
hematoma required intervention was comparable to the control
group. The importance of this issue lies in the fact that for using
beneﬁcial effects of CRT, other treatments controlling CRT
complications should be considered for the patients, such as
appropriate prophylactic antibiotics along with CRT implant
placement in order to decrease the risk of infection, accurate
radiographic and clinical investigations regarding pneumothorax,
and opportune intervention when such complications appear.
Previous studies found that CRT could signiﬁcantly increase the
incidence of LV lead repositioning, infection, pneumothorax,
hematoma, and coronary venus dissection. Although many of
these adverse events did not have substantial long-term con-
sequences, they may have caused substantial morbidity and
increased the overall costs to health care system.28–30
Burri et al. argued that although CRT improved patients’
outcome, this was at the expense of a greater rate of device-related
complications such as infections and stimulation of phrenic nerve
and lead repositioning compared with ICD implantation.31 RAFT
reported that patients with NYHA class II or III heart failure, a wide
QRS complex, and left ventricular systolic dysfunction, the addition
of CRT to an ICD reduced rates of death and hospitalization for
heart failure. This improvement was accompanied by more
adverse events such as left ventricular lead dislodgment and
infection.16 MADIT-CRT showed that CRT was associated with a
signiﬁcant decrease of mortality and HF events during 7 years
follow-up in patients with mild HF symptoms, left ventricular
dysfunction and left bundle-branch block.20 Also the results of a 5-
year-follow-up (REVERSE study) indicated that in patients with
mild HF, CRT produced reverse LV remodeling, accompanied by
very low mortality and need for HF hospitalization. CRT in addition
to optimal medical therapy produced long-term clinical beneﬁts in
mild HF.21 On the other hand, several studies examined medical
costs in patients with mild HF, strongly emphasizing that CRT
reduced total medical costs in patients with asymptomatic and
mild HF compared to optimal medical therapy.22–24
5. Limitation
Our study is associated with several limitations. Data from
some end-points of interest were not available for all studies, and
we did not contact the authors to obtain unpublished data.
Additionally, the absence of patient-level data limits our ability to
assess sensitive patient-based subgroup analysis about effects of
CRT on clinical or functional outcomes.
6. Conclusion
Finally it is concluded that implantation of CRT in patients with
asymptomatic and mild HF resulted in improved cardiac function,
decreased progression of HF from mild to severe, reduced mortality
in short to long-term follow-up. Although risk of complications
such as infection, and pneumothorax increased after implantation
of CRT, it is recommended to recognize the complications at earlier
stages and use supplementary treatments and appropriate
controls. As CRT also reduces medical costs in patients with mild
HF compared with optimal medical therapy we strongly recom-
mend this treatment strategy for patients with mild HF as an
economical treatment with high efﬁciency.
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